Open: 28.99 Close: 29.39 Change: 0.4

Today's Summary

Celldex Therapeutics, Inc., Viridian Therapeutic and Inc.’s stock is NA in 2026, NA in the previous five trading days and up 47.31% in the past year. The company engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune and other diseases. Viridian is advancing multiple late-stage, anti-insulin-like growth factor-1 receptor (IGF-1R) candidates in the clinic for the treatment of patients with thyroid eye disease (TED) Viridian Therapeutics is also advancing elegrobart (VRDN-003) as a potential best-in-class subcutaneous therapy.